Antipsychotic polypharmacy: never say never, but never say always

The merits and pitfalls of this approach have been much debated by this editorialist (2–7) and within the pages of this journal (8, 9) and also by many others [e.g. 10–16; see also references in (1)]. Antipsychotic polypharmacy ⁄ combination treatments are associated with higher medication costs, more side effects, no clearly documented improvement in efficacy, and worse outcomes (e.g. 1). So, why do we keep doing it and in fact why are we increasing our use of antipsychotic polypharmacy ⁄ combinations?

[1]  R. Cardinal.  Case Studies: Stahl’s Essential Psychopharmacology , 2012 .

[2]  R. Kilian,et al.  Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment , 2012, Acta psychiatrica Scandinavica.

[3]  Alexander L. Miller,et al.  Effectiveness of switching from antipsychotic polypharmacy to monotherapy. , 2011, The American journal of psychiatry.

[4]  The psychotic arsonist who burned his house and tried to burn himself , 2011, Case Studies: Stahl's Essential Psychopharmacology.

[5]  O. Spigset,et al.  Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies , 2010, Acta psychiatrica Scandinavica.

[6]  S. Stahl.  How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient , 2010, Acta psychiatrica Scandinavica.

[7]  H. Lublin,et al.  Evaluation of a multifaceted intervention to limit excessive antipsychotic co‐prescribing in schizophrenia out‐patients , 2010, Acta psychiatrica Scandinavica.

[8]  C. Correll,et al.  10‐Year trends in the treatment and outcomes of patients with first‐episode schizophrenia , 2010, Acta psychiatrica Scandinavica.

[9]  B. Bégaud,et al.  Antipsychotic prescribing trends: a review of pharmaco‐epidemiological studies , 2010, Acta psychiatrica Scandinavica.

[10]  C Michael Stein,et al.  Atypical antipsychotic drugs and the risk of sudden cardiac death. , 2009, The New England journal of medicine.

[11]  C. Correll,et al.  Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. , 2009, Schizophrenia bulletin.

[12]  S. Stahl,et al.  A successful antipsychotic combination trial. Quo Vadis? , 2004, Acta psychiatrica Scandinavica.

[13]  S. Stahl.  Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? , 2004, The international journal of neuropsychopharmacology.

[14]  S. Stahl,et al.  A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. , 2004, Current medicinal chemistry.

[15]  S. Stahl.  Antipsychotic polypharmacy: evidence based or eminence based? , 2002, Acta psychiatrica Scandinavica.

[16]  S. Stahl.  Antipsychotic polypharmacy: squandering precious resources? , 2002, The Journal of clinical psychiatry.

[17]  S. Kapur,et al.  Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. , 2001, The American journal of psychiatry.

[18]  S. Stahl.  Antipsychotic polypharmacy, part 2: tips on use and misuse. , 1999, The Journal of clinical psychiatry.

[19]  S. Stahl,et al.  Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? , 1999, The Journal of clinical psychiatry.

[20]  S. Stahl,et al.  Best Practices in Medical Teaching: Measuring outcomes and ensuring success , 2011 .

[21]  S. Stahl,et al.  High-cost use of second-generation antipsychotics under California's Medicaid program. , 2006, Psychiatric Services.